Neurobiogen
Thursday, June 06, 2024
CNS/Neurological
Company Presentation Theater 2
NEUROBIOGEN prioritizes its research and development efforts to develop innovative new medicine to treat patients who suffer from degenerative brain diseases and central nervous system diseases. By developing innovative drugs through the efficacy verification and clinical progress of our new drug candidates (KDS2010/Tisolagiline), we will continue our journey to a global company to contribute to human health after all.
Company Website:
https://www.neurobiogen.com/eng/main/
Lead Product in Development:
KDS2010 (Tisolagiline) which is new creative small molecule Drug targeting CNS Diseases like Alzheimer's Disease, Obesity, Parkinson's Disease, Spinalcord injury, Stroke and metabolic inflammatory diseases.
Company HQ City
Seoul
Company HQ State
Seoul
Company HQ Country
Korea, Republic of
CEO/Top Company Official
Sangwook Kim
Development Phase of Primary Product
Phase II
Primary Speaker
.jpg)
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())